Polyneuropathy, anti-tuberculosis treatment and the role of pyridoxine in the HIV/AIDS era: A systematic review

International Journal of Tuberculosis and Lung Disease

Volumn 15, Issue 6, 2011, Pages

  Van Der Watt, J J ^a   Harrison, T B ^b   Benatar, M ^b   Heckmann, J M ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

HIV; Isoniazid; Peripheral neuropathy; Pyridoxine; Tuberculosis; Vitamin B6

Indexed keywords

CYCLOSERINE; DIDANOSINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; PYRIDOXINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; STREPTOMYCIN; ZALCITABINE;

ACETYLATION; ASTHENIA; CLINICAL FEATURE; DEPRESSION; DROWSINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GLUCOSE METABOLISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MALNUTRITION; MIXED INFECTION; MORBIDITY; MORTALITY; NERVE DEGENERATION; NEUROPATHY; NEUROTOXICITY; OPTIC NERVE DISEASE; OTOTOXICITY; PERIPHERAL NEUROPATHY; PHOSPHORYLATION; POLYNEUROPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

ANTITUBERCULAR AGENTS; HIV INFECTIONS; HUMANS; ISONIAZID; POLYNEUROPATHIES; PRACTICE GUIDELINES AS TOPIC; PYRIDOXINE; TUBERCULOSIS; VITAMIN B COMPLEX;

EID: 79955802564     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.10.0284     Document Type: Review

References (77)

1. World Health Organization. Global tuberculosis control: epidemiology, strategy, financing. WHO/HTM/TB/2009.411. Geneva, Switzerland: WHO, 2009. http://whqlibdoc.who.int/publications/2009/9789241563802-eng.pdf Accessed February 2011.
2. Harries A D, Hargreaves N J, Kemp J, et al. Deaths from tuberculosis in sub-Saharan African countries with a high prevalence of HIV-1. Lancet 2001; 357: 1519-1523. (Pubitemid 32488877)
3. Breen R A, Miller R F, Gorsuch T, et al. Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection. Thorax 2006; 61: 791-794. (Pubitemid 44369404)
4. Marks D J, Dheda K, Dawson R, Ainslie G, Miller R F. Adverse events to antituberculosis therapy: influence of HIV and antiretroviral drugs. Int J STD AIDS 2009; 20: 339-345.
5. Biehl J P, Nimitz H J. Studies on the use of high dose of isoniazid. I. Toxicity studies. Am Rev Tuberc 1954; 70: 430-441.
6. Argov Z, Mastaglia F L. Drug-induced peripheral neuropathies. BMJ 1979; 1: 663-666. (Pubitemid 9128185)
7. Snider D E Jr. Pyridoxine supplementation during isoniazid therapy. Tubercle 1980; 61: 191-196.
8. Centers for Disease Control and Prevention. Treatment of tuberculosis. Atlanta, GA, USA: American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America, 2003.
9. South African Department of Health. South African tuberculosis control programme practical guidelines 2004. Pretoria, South Africa: Department of Health, 2004. http://www.kznhealth.gov.za/chrp/documents/Guidelines/Guidelines- National/T uberculosis/SA-TB-Guidelines-2004.pdf Accessed February 2010.
10. Maritz J, Benatar M, Dave J A, et al. HIV neuropathy in South Africans: frequency, characteristics, and risk factors. Muscle Nerve 2010; 41: 599-606.
11. Biehl J P, Sklavem J H. Toxicity of isoniazid. Am Rev Tuberc 1953; 68: 296-297.
12. Jones W A, Jones G P. Peripheral neuropathy due to isoniazid; report of two cases. Lancet 1953; 1: 1073-1074.
13. Lubing H N. Peripheral neuropathy in tuberculosis patients treated with isoniazid. Am Rev Tuberc 1953; 68: 458-461.
14. Mandel W. Pyridoxine and the isoniazid-induced neuropathy. Dis Chest 1959; 36: 293-296.
15. Biehl J P, Vilter R W. Effect of isoniazid on vitamin B6 metabolism; its possible significance in producing isoniazid neuritis. Proc Soc Exp Biol Med 1954; 85: 389-392.
16. Oestreicher R, Dressler S H, Middlebrook G. Peripheral neuritis in tuberculous patients treated with isoniazid. Am Rev Tuberc 1954; 70: 504-508.
17. Goldman A L, Braman S S. Isoniazid: a review with emphasis on adverse effects. Chest 1972; 62: 71-77.
18. Ochoa J. Isoniazid neuropathy in man: quantitative electron microscope study. Brain 1970; 93: 831-850.
19. Morales S M, Lincoln E M. The effect of isoniazid therapy on pyridoxine metabolism in children. Am Rev Tuberc 1957; 75: 594-600.
20. McIlleron H, Willemse M, Werely C J, et al. Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: implications for international pediatric dosing guidelines. Clin Infect Dis 2009; 48: 1547-1553.
21. Preziosi P. Isoniazid: metabolic aspects and toxicological correlates. Curr Drug Metab 2007; 8: 839-851. (Pubitemid 350238914)
22. Evans D A, Manley K A, McKusick V A. Genetic control of isoniazid metabolism in man. BMJ 1960; 2: 485-491.
23. Parkin D P, Vandenplas S, Botha F J, et al. Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. Am J Respir Crit Care Med 1997; 155: 1717-1722. (Pubitemid 27216683)
24. Kinzig-Schippers M, Tomalik-Scharte D, Jetter A, et al. Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? Antimicrob Agents Chemother 2005; 49: 1733-1738.
25. Krishnamurthy D V, Selkon J B, Ramachandran K, et al. Effect of pyridoxine on vitamin B6 concentrations and glutamicoxaloacetic transaminase activity in whole blood of tuberculous patients receiving high-dosage isoniazid. Bull World Health Organ 1967; 36: 853-870.
26. Matar K M, Mayet A Y, Ayoola E A, Bawazir S A, Al-Faleh F Z, Al-Wazzan A. Isoniazid acetylation phenotyping in Saudi Arabs. J Clin Pharm Ther 2004; 29: 443-447. (Pubitemid 39457469)
27. Bach P H, Higgins-Opitz S B, Bima B, Leary W P. Isoniazid acetylator status of Black South African tuberculosis patients. S Afr Med J 1976; 50: 1132-1134.
28. Eidus L, Glatthaar E, Hodgkin M M, Nel E E, Kleeberg H H. Phenotyping of South African Black tuberculosis patients for inactivation of isoniazid. Res Commun Chem Pathol Pharmacol 1979; 23: 243-256. (Pubitemid 9124315)
29. Timperio A M, Rinalducci S, Zolla L. Hydrazide derivatives produce active oxygen species as hydrazine. Bioorg Chem 2005; 33: 459-469. (Pubitemid 41674459)
30. Israel N, Gougerot-Pocidalo M A, Aillet F, Virelizier J L. Redox status of cells influences constitutive or induced NF-kappa B translocation and HIV long terminal repeat activity in human T and monocytic cell lines. J Immunol 1992; 149: 3386-3393.
31. Allard J P, Aghdassi E, Chau J, Salit I, Walmsley S. Oxidative stress and plasma antioxidant micronutrients in humans with HIV infection. Am J Clin Nutr 1998; 67: 143-147. (Pubitemid 28037639)
32. Kumar N. Nutritional neuropathies. Neurol Clin 2007; 25: 209-255. (Pubitemid 46283309)
33. Chiang E P, Smith D E, Selhub J, Dallal G, Wang Y C, Roubenoff R. Inflammation causes tissue-specific depletion of vitamin B6. Arthritis Res Ther 2005; 7: R1254-1262.
34. Visser M E, Texeira-Swiegelaar C, Maartens G. The short-term effects of anti-tuberculosis therapy on plasma pyridoxine levels in patients with pulmonary tuberculosis. Int J Tuberc Lung Dis 2004; 8: 260-262. (Pubitemid 38622936)
35. Steichen O, Martinez-Almoyna L, De Broucker T. Isoniazid induced neuropathy: consider prevention. Rev Mal Respir 2006; 23: 157-160. (Pubitemid 43926741)
36. Buss J L, Ponka P. Hydrolysis of pyridoxal isonicotinoyl hydrazone and its analogs. Biochim Biophys Acta 2003; 1619: 177-186. (Pubitemid 36078355)
37. Tower D B. Neurochemical aspects of pyridoxine metabolism and function. Am J Clin Nutr 1956; 4: 329-345.
38. Marks J. A guide to the vitamins: their role in health and disease. Lancaster, UK: Medical and Technical Publishing Co, 1975.
39. Carlson H B, Anthony E M, Russell W F Jr, Middlebrook G. Prophylaxis of isoniazid neuropathy with pyridoxine. N Engl J Med 1956; 255: 119-122.
40. World Health Organization. Treatment of tuberculosis: guide lines for national programmes. 3rd ed. Geneva, Switzerland: WHO, 2003.
41. Centers for Disease Control and Prevention. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. Atlanta, GA, USA: CDC, 2009.
42. Chan E D, Iseman M D. Current medical treatment for tuberculosis. BMJ 2002; 325: 1282-1286. (Pubitemid 35430589)
43. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Joint Tuberculosis Committee of the British Thoracic Society. Thorax 1998; 53: 536-548.
44. Nisar M, Watkin S W, Bucknall R C, Agnew R A. Exacerbation of isoniazid induced peripheral neuropathy by pyridoxine. Thorax 1990; 45: 419-420. (Pubitemid 20184906)
45. Fennerty T. Pulmonary embolism. Hospitals should develop their own strategies for diagnosis and management. BMJ 1998; 317: 91-92. (Pubitemid 28310611)
46. South African Department of Health. South African national guidelines on nutrition for people living with TB, HIV/AIDS and other chronic debilitating conditions. Pretoria, South Africa: Department of Health, 2001. http://www.sahealthinfo.org/nutrition/sanational1.pdf Accessed February 2010.
47. Gibbon C J, Blockman M. South African medicines formulary. 8th ed. Cape Town, South Africa: Health and Medical Publishing Group of the South African Medical Association, 2008.
48. South African Department of Health. Standardised management of multidrug-resistant tuberculosis in South Africa. Pretoria, South Africa: Department of Health, 2004. http://www.sahealthinfo.net/tb/mdrtbguidelines.pdf Accessed April 2010.
49. Boone I U, Woodward K T. Relationship of pyridoxine and its derivatives to the mechanism of action of isoniazid. Proc Soc Exp Biol Med 1953; 84: 292-296.
50. Ungar J, Tomich E G, Parkin K R, Muggleton P W. Effect of pyridoxine on the action of isoniazid. Lancet 1954; 267: 220-221.
51. McCune R, Deuschle K, McDermott W. The delayed appearance of isoniazid antagonism by pyridoxine in vivo. Am Rev Tuberc 1957; 76: 1100-1105.
52. Schaumburg H, Kaplan J, Windebank A, et al. Sensory neuropathy from pyridoxine abuse. A new megavitamin syndrome. N Engl J Med 1983; 309: 445-448. (Pubitemid 13041483)
53. Parry G J, Bredesen D E. Sensory neuropathy with low-dose pyridoxine. Neurology 1985; 35: 1466-1468. (Pubitemid 15242422)
54. Bernstein A L. Vitamin B6 in clinical neurology. Ann N Y Acad Sci 1990; 585: 250-260.
55. Bendich A, Cohen M. Vitamin B6 safety issues. Ann N Y Acad Sci 1990; 585: 321-330.
56. Hathcock J N. Vitamins and minerals: efficacy and safety. Am J Clin Nutr 1997; 66: 427-437. (Pubitemid 27360344)
57. Lanternier F, Dalban C, Perez L, Bricaire F, Costagliola D, Caumes E. Tolerability of anti-tuberculosis treatment and HIV sero status. Int J Tuberc Lung Dis 2007; 11: 1203-1209. (Pubitemid 350146301)
58. Dean G L, Edwards S G, Ives N J, et al. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS 2002; 16: 75-83. (Pubitemid 34062184)
59. Schifitto G, McDermott M P, McArthur J C, et al. Incidence of and risk factors for HIV-associated distal sensory polyneuropathy. Neurology 2002; 58: 1764-1768. (Pubitemid 34663575)
60. Westreich D J, Sanne I, Maskew M, et al. Tuberculosis treatment and risk of stavudine substitution in first-line antiretroviral therapy. Clin Infect Dis 2009; 48: 1617-1623.
61. Patel A, Patel K, Patel J, Shah N, Patel B, Rani S. Safety and antiretroviral effectiveness of concomitant use of rifampicin and efavirenz for antiretroviral-naive patients in India who are coinfected with tuberculosis and HIV-1. J Acquir Immune Defic Syndr 2004; 37: 1166-1169. (Pubitemid 39166652)
62. Forna F, Liechty C A, Solberg P, et al. Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr 2007; 44: 456-462. (Pubitemid 46555382)
63. van Lettow M, Fawzi W W, Semba R D. Triple trouble: the role of malnutrition in tuberculosis and human immunodeficiency virus co-infection. Nutr Rev 2003; 61: 81-90. (Pubitemid 37259961)
64. Karyadi E, Schultink W, Nelwan R H, et al. Poor micronutrient status of active pulmonary tuberculosis patients in Indonesia. J Nutr 2000; 130: 2953-2958. (Pubitemid 32005324)
65. Tang A M, Smit E. Selected vitamins in HIV infection: a review. AIDS Patient Care STDS 1998; 12: 263-273. (Pubitemid 28279947)
66. Villamor E, Mugusi F, Urassa W, et al. A trial of the effect of micronutrient supplementation on treatment outcome, T cell counts, morbidity, and mortality in adults with pulmonary tuberculosis. J Infect Dis 2008; 197: 1499-1505. (Pubitemid 351706478)
67. Anabwani G, Navario P. Nutrition and HIV/AIDS in sub-Saharan Africa: an overview. Nutrition 2005; 21: 96-99. (Pubitemid 40136564)
68. Beach R S, Mantero-Atienza E, Shor-Posner G, et al. Specific nutrient abnormalities in asymptomatic HIV-1 infection. AIDS 1992; 6: 701-708.
69. Fawzi W W, Msamanga G I, Spiegelman D, et al. A randomized trial of multivitamin supplements and HIV disease progression and mortality. N Engl J Med 2004; 351: 23-32. (Pubitemid 38857244)
70. Kaiser J D, Campa A M, Ondercin J P, Leoung G S, Pless R F, Baum M K. Micronutrient supplementation increases CD4 count in HIV-infected individuals on highly active antiretroviral therapy: a prospective, double-blinded, placebo-controlled trial. J Acquir Immune Defic Syndr 2006; 42: 523-528. (Pubitemid 44162419)
71. Leibold J E. The ocular toxicity of ethambutol and its relation to dose. Ann N Y Acad Sci 1966; 135: 904-909.
72. Tugwell P, James S L. Peripheral neuropathy with ethambutol. Postgrad Med J 1972; 48: 667-670.
73. Donomae I, Yamamoto K. Clinical evaluation of ethambutol in pulmonary tuberculosis. Ann N Y Acad Sci 1966; 135: 849-881.
74. Snavely S R, Hodges G R. The neurotoxicity of antibacterial agents. Ann Intern Med 1984; 101: 92-104. (Pubitemid 14088076)
75. Poole G W, Schneeweiss J. Peripheral neuropathy due to ethioniamide. Am Rev Respir Dis 1961; 84: 890-892.
76. Johns Hopkins Point of Care Information Technology Centre. Cycloserine. ABX guide. Baltimore, MD, USA: Johns Hopkins POC-IT, 2009. http://hopkins- abxguide.org Accessed December 2010.
77. Wood R, Middelkoop K, Myer L, et al. Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control. Am J Respir Crit Care Med 2007; 175: 87-93. (Pubitemid 46105314)